secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001770787-24-000064
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%
--------------------------------------------------------------------------------

- Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).
- Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).
- CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.
- Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/0001770787-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/txg-20241009.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer